PMID- 30169514
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190610
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 8
DP  - 2018
TI  - Identifying the morphologic basis for radiomic features in distinguishing
      different Gleason grades of prostate cancer on MRI: Preliminary findings.
PG  - e0200730
LID - 10.1371/journal.pone.0200730 [doi]
AB  - Translation of radiomics into the clinic may require a more comprehensive
      understanding of the underlying morphologic tissue characteristics they reflect. 
      In the context of prostate cancer (PCa), some studies have correlated gross
      histological measurements of gland lumen, epithelium, and nuclei with disease
      appearance on MRI. Quantitative histomorphometry (QH), like radiomics for
      radiologic images, is the computer based extraction of features for describing
      tumor morphology on digitized tissue images. In this work, we attempt to
      establish the histomorphometric basis for radiomic features for prostate cancer
      by (1) identifying the radiomic features from T2w MRI most discriminating of low 
      vs. intermediate/high Gleason score, (2) identifying QH features correlated with 
      the most discriminating radiomic features previously identified, and (3)
      evaluating the discriminative ability of QH features found to be correlated with 
      spatially co-localized radiomic features. On a cohort of 36 patients (23 for
      training, 13 for validation), Gabor texture features were identified as being
      most predictive of Gleason grade on MRI (AUC of 0.69) and gland lumen shape
      features were identified as the most predictive QH features (AUC = 0.75). Our
      results suggest that the PCa grade discriminability of Gabor features is a
      consequence of variations in gland shape and morphology at the tissue level.
FAU - Penzias, Gregory
AU  - Penzias G
AUID- ORCID: 0000-0002-5408-6810
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States of America.
FAU - Singanamalli, Asha
AU  - Singanamalli A
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States of America.
FAU - Elliott, Robin
AU  - Elliott R
AD  - University Hospitals, Cleveland, OH, United States of America.
FAU - Gollamudi, Jay
AU  - Gollamudi J
AD  - University Hospitals, Cleveland, OH, United States of America.
FAU - Shih, Natalie
AU  - Shih N
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, PA, United
      States of America.
FAU - Feldman, Michael
AU  - Feldman M
AD  - Department of Pathology, University of Pennsylvania, Philadelphia, PA, United
      States of America.
FAU - Stricker, Phillip D
AU  - Stricker PD
AD  - St. Vincent's Prostate Cancer Clinic, Darlinghurst, NSW, Australia.
FAU - Delprado, Warick
AU  - Delprado W
AD  - Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
FAU - Tiwari, Sarita
AU  - Tiwari S
AD  - Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst,
      NSW, Australia.
FAU - Bohm, Maret
AU  - Bohm M
AD  - Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst,
      NSW, Australia.
FAU - Haynes, Anne-Maree
AU  - Haynes AM
AD  - Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst,
      NSW, Australia.
FAU - Ponsky, Lee
AU  - Ponsky L
AD  - University Hospitals, Cleveland, OH, United States of America.
FAU - Fu, Pingfu
AU  - Fu P
AD  - Department of Population and Quantitative Health Sciences, Case Western Reserve
      University, Cleveland, OH, United States of America.
FAU - Tiwari, Pallavi
AU  - Tiwari P
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States of America.
FAU - Viswanath, Satish
AU  - Viswanath S
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States of America.
FAU - Madabhushi, Anant
AU  - Madabhushi A
AD  - Department of Biomedical Engineering, Case Western Reserve University, Cleveland,
      OH, United States of America.
LA  - eng
SI  - Dryad/10.5061/dryad.b3d257g
GR  - R21 CA179327/CA/NCI NIH HHS/United States
GR  - R21 CA195152/CA/NCI NIH HHS/United States
GR  - R01 CA216579/CA/NCI NIH HHS/United States
GR  - R01 CA208236/CA/NCI NIH HHS/United States
GR  - U24 CA199374/CA/NCI NIH HHS/United States
GR  - R01 DK098503/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180831
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Humans
MH  - Image Interpretation, Computer-Assisted/*methods
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Neoplasm Grading
MH  - Prostatic Neoplasms/*classification/*pathology
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Retrospective Studies
PMC - PMC6118356
COIS- I have read the journal's policy and the authors of this manuscript have the
      following competing interests: Dr. Madabhushi is the co-founder and stake holder 
      in Ibris Inc., a cancer diagnostics company. Additionally he is also an equity
      holder in Elucid Bioimaging and in Inspirata. He is also a scientific advisory
      consultant for Inspirata, and holds a joint NIH R01 grant with them. Dr.
      Viswanath is a scientific advisory board member and equity holder in Virbio, Inc.
      This does not alter our adherence to PLOS ONE policies on sharingdata and
      materials.
EDAT- 2018/09/01 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/09/01 06:00
PHST- 2017/07/20 00:00 [received]
PHST- 2018/07/02 00:00 [accepted]
PHST- 2018/09/01 06:00 [entrez]
PHST- 2018/09/01 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
AID - 10.1371/journal.pone.0200730 [doi]
AID - PONE-D-17-27281 [pii]
PST - epublish
SO  - PLoS One. 2018 Aug 31;13(8):e0200730. doi: 10.1371/journal.pone.0200730.
      eCollection 2018.